Compare · EMBC vs MDLN
EMBC vs MDLN
Side-by-side comparison of Embecta Corp. (EMBC) and Medline Inc. (MDLN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EMBC and MDLN operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $44.15B, about 220.2x EMBC ($200.5M).
- Over the past year, EMBC is down 66.0% and MDLN is down 18.2% - MDLN leads by 47.8 points.
- MDLN has been more active in the news (20 items in the past 4 weeks vs 5 for EMBC).
- MDLN has more recent analyst coverage (25 ratings vs 9 for EMBC).
- Company
- Embecta Corp.
- Medline Inc.
- Price
- $3.37-0.59%
- $33.33-0.80%
- Market cap
- $200.5M
- $44.15B
- 1M return
- -6.65%
- -20.61%
- 1Y return
- -65.99%
- -18.16%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2025
- News (4w)
- 5
- 20
- Recent ratings
- 9
- 25
Embecta Corp.
Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety devices, as well as digital applications to assist people with managing their diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is based in Parsippany, New Jersey. Embecta Corp.(NasdaqGS:EMBC) operates independently of Becton, Dickinson and Company as of April 1, 2022.
Latest EMBC
- Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
- VP, Chief Accounting Officer Roth Anthony M. was granted 30,000 shares, increasing direct ownership by 61% to 78,833 units (SEC Form 4)
- embecta to Participate in Investor Events
- Amendment: SEC Form SCHEDULE 13G/A filed by Embecta Corp.
- SEC Form SD filed by Embecta Corp.
- Embecta Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits
- embecta Completes Acquisition of Owen Mumford Holdings Limited
- embecta to Participate at the 2026 BofA Securities Global Health Care Conference
- Embecta Corp. downgraded by BTIG Research
- SEC Form SCHEDULE 13G filed by Embecta Corp.
Latest MDLN
- Medline Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Entry into a Material Definitive Agreement
- Large owner Hellman & Friedman Capital Partners X (Parallel), L.P. sold $1,164,385,709 worth of shares (31,868,237 units at $36.54) and disposed of 1,887,801 shares (SEC Form 4)
- Director Healy Patrick J acquired 202,106 shares, increasing direct ownership by 15% to 1,387,921 units (SEC Form 4)
- Large owner Bx Mozart Ml-2 Holdco L.P. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Large owner Bcp 8 Holdings Mozart Manager L.L.C. sold $1,217,349,994 worth of shares (33,317,824 units at $36.54) and disposed of 438,214 shares (SEC Form 4)
- Medline's Prime Vendor model expands outside the United States
- Medline Inc. announces closing of upsized secondary offering of Class A common stock
- Medline announces participation in upcoming investor conferences
- MediWound Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Large owner Bx Mozart Ml-1 Holdco L.P. converted options into 11,348,698 shares and disposed of 11,348,698 units of Class B Common Stock (SEC Form 4)